Risk factors
HAP/VAP
cIAI
cUTI
Certain patient factors increase the risk of MDR Gram-negative infections1–5
cIAI, complicated intra-abdominal infection; COPD, chronic obstructive pulmonary disease; CRE, carbapenem resistant Enterobacterales; cUTI, complicated urinary tract infection; HAP, hospital acquired pneumonia; ICU, intensive care unit; MDR, multidrug-resistant; VAP, ventilator-associated pneumonia.References1. Bassetti M, Carnelutti A, Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Exp Rev Anti Infect Ther. 2017;15:55–65; 2. Miller BM, Johnson SW. Demographic and infection characteristics of patients with carbapenem-resistant Enterobacteriaceae in a community hospital: Development of a bedside clinical score for risk assessment. Am J Infect Control. 2016;44:134–7; 3. De Waele JJ, De Waele JJ, Akova M, Antonelli M, et al. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Med. 2018;44:189–196; 4. Albur M, Hamilton F, MacGowan AP. Early warning score: a dynamic marker of severity and prognosis in patients with Gram-negative bacteraemia and sepsis. Ann Clin Microbiol Antimicrob. 2016;15:23; 5. Harris AD, Harris AD, McGregor JC, Johnson JA, et al. Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 2007;13:1144–1149.
The example described here is not an actual patient, but rather a fictitious representation of a scenario for which Ceftazidime/Avibactam Pfizer could be considered.Patient risk factors for a MDR Gram-negative infection
cIAI, complicated intra-abdominal infection; COPD, chronic obstructive pulmonary disease; cUTI, complicated urinary tract infection; HAP, hospital acquired pneumonia; MDR, multidrug-resistant; VAP, ventilator-associated pneumonia.
The example described here is not an actual patient, but rather a fictitious representation of a scenario for which Ceftazidime/Avibactam Pfizer could be considered.Patient risk factors for a MDR Gram-negative infection
cIAI, complicated intra-abdominal infection; COPD, chronic obstructive pulmonary disease; CRE, carbapenem resistant Enterobacterales; cUTI, complicated urinary tract infection; HAP, hospital acquired pneumonia; ICU, intensive care unit; IV, intravenous; MDR, multidrug-resistant; VAP, ventilator-associated pneumonia.
The example described here is not an actual patient, but rather a fictitious representation of a scenario for which Ceftazidime/Avibactam Pfizer could be considered.Patient risk factors for a MDR Gram-negative infection
cIAI, complicated intra-abdominal infection; COPD, chronic obstructive pulmonary disease; CRE, carbapenem resistant Enterobacterales; cUTI, complicated urinary tract infection; HAP, hospital acquired pneumonia; ICU, intensive care unit; IV, intravenous; MDR, multidrug-resistant; VAP, ventilator-associated pneumonia.